{
  "trial_id": "NCT00135200",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age \u2265 18 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Expected survival \u2265 6 months",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Pre-study performance status of 0, 1, or 2 according to the World Health Organization (WHO)",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Newly diagnosed or relapsed/refractory myeloma with histologic confirmation of multiple myeloma by the Department of Pathology at University of Michigan Cancer Center (UMCC)",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Not more than 3 lines of therapy for myeloma for patients with relapsed disease",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Documented Stage II or III multiple myeloma (Durie and Salmon, 1975) prior to initiation of first line therapy",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "At least 4 cycles of first line (for newly diagnosed patients) or salvage (for relapsed/refractory patients) prior therapy and in a plateau of at least partial response (Blade et al, 1999) for at least 2 determinations 6 weeks apart",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "At least 21 days from day 1 of the last cycle and fully recovered from all toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Measurable M-proteins with greater than 1 g/dl serum monoclonal protein and/or greater than 0.5 g/24 hour urine light chain excretion",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Acceptable hematologic status within two weeks prior to patient registration, including: Absolute neutrophil count ([segmented neutrophils + bands] x total white blood cell [WBC]) \u2265 1,500/mm3;",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Platelet counts \u2265 150,000/mm3; these patients will receive total body dose of 75 cGy of Bexxar; or Platelet counts from 100,000/mm3 to 149,000/mm3; these patients will receive a 65 cGy total body dose of Bexxar;",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "In patients previously treated with ASCT, total body dose will be 55 cGy in patients with platelet count > 150,000 and 45 cGy in patients with platelets 100,000-149,000.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Female patients who are not pregnant or lactating",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients with impaired bone marrow reserve, as indicated by one or more of the following:",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Platelet count < 100,000 cells/mm3;",
      "label": "triggers",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has multiple myeloma with recurrent disease and systemic amyloidosis. She is on hemodialysis for ESRD and represents with malaise, weakness, and generalized body aching.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT00135200",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}